ArticleLancet regional health. Americas2026
Affordability of new drugs in the Brazilian public health system: a 13-year monitoring analysis of reimbursement decisions based on health technology assessments (2012-2024).
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In low- and middle-income countries, reimbursement decisions often rely on projected incremental budget impact (IBI) analyses. We assessed whether drug incorporations into the Brazilian public health system (SUS) between 2012 and 2024 were consistent with affordability considerations within the health technology assessment (HTA) framework. Methods: A retrospective documentary analysis was conducted using technical recommendation reports issued by the Brazilian National Committee for Health Technology Incorporation (Conitec). The primary variable was the total projected IBI of incorporated drugs. Subgroup analyses were performed by year of incorporation, health condition, and budget impact output. The proportion of total projected IBI relative to the Specialized Component of Pharmaceutical Care (CEAF) budget was assessed. Findings: A total of 199 incorporated drugs were analyzed, 64 of which were projected to be cost-saving (Int$ 6·67 billion). These savings exceeded the total positive projected IBI generated by the remaining drugs (Int$ 4·05 billion). When COVID-19 vaccines were excluded, the cumulative projected IBI became positive, totaling Int$ 2·80 billion over the period analyzed, with sensitivity analyses yield estimates ranging from Int$ 2·36 billion to Int$ 2·88 billion. Preventable diseases exhibited the lowest median per capita IBI (Int$ 28; IQR Int$ 15; IQR Int$ 132), and oncological diseases the highest (Int$ 23,550; IQR Int$ 6789; IQR Int$ 57,154). Among drugs reimbursed exclusively by the Ministry of Health, the cumulative projected IBI represented 29% of the CEAF budget in 2024, exceeding 45% from 2019 to 2022. Interpretation: The findings suggest that Conitec's decisions were consistent with HTA principles related to affordability. This interpretation is based on the evidence available at the time of the HTA decision rather than on observed real-world data following incorporation into the SUS. Funding: None.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.